Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB-WT) Accumulated Expenses (2023 - 2025)

Nuvation Bio (NUVB-WT) has disclosed Accumulated Expenses for 3 consecutive years, with $45.2 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 37.61% to $45.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $45.2 million through Dec 2025, up 37.61% year-over-year, with the annual reading at $45.2 million for FY2025, 37.61% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $45.2 million at Nuvation Bio, up from $32.6 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $45.2 million in Q4 2025, with the low at $8.4 million in Q1 2023.
  • Average Accumulated Expenses over 3 years is $21.1 million, with a median of $21.7 million recorded in 2024.
  • The sharpest move saw Accumulated Expenses surged 235.27% in 2024, then rose 20.15% in 2025.
  • Over 3 years, Accumulated Expenses stood at $9.8 million in 2023, then soared by 235.27% to $32.8 million in 2024, then soared by 37.61% to $45.2 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $45.2 million, $32.6 million, and $24.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.